Creating new treatments for cancers driven by the CCNE1 gene
Official title: Development of bifunctional CDK2 inhibitors for treatment of CCNE1-driven cancers
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11061933 · Data updated 2026-11-12
This study is working on new medications that target a specific protein to help treat high-grade serous ovarian cancer linked to the CCNE1 gene, aiming to create options for patients who don’t have many treatments available.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $196,934 |
| NIH project number | 5R21CA288927-02 |
| Project ID | NIH-11061933 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with high-grade serous ovarian cancer or other cancers characterized by CCNE1 amplification.
✕Less likely to help
Patients with cancers not driven by CCNE1 or those who do not have high-grade serous ovarian cancer may not benefit from this research.
What this research studies
This research focuses on developing new drugs that specifically target CDK2, a protein involved in cell cycle regulation, to treat cancers associated with the CCNE1 gene, particularly high-grade serous ovarian cancer. The approach involves designing bifunctional inhibitors that can selectively inhibit CDK2 without affecting similar proteins, which is crucial for minimizing side effects. By addressing the overactivity of CCNE1, the research aims to provide a novel therapeutic option for patients who currently have limited treatment choices. The study will utilize advanced biochemical techniques to identify and optimize these inhibitors.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with CCNE1-driven cancers, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in targeting CDK2 for cancer treatment, indicating that this approach may lead to significant advancements in therapy.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Schonbrunn, Ernst — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Schonbrunn, Ernst
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.